Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Chalazion × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Completed 6 Unknown 2 Withdrawn 1 Terminated 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 403 Neoplasms 276 Carcinoma, Non-Small-Cell Lung 226 Prostatic Neoplasms 213 Lung Neoplasms 147 Colorectal Neoplasms 145 Pancreatic Neoplasms 130 Leukemia, Myeloid, Acute 128 Neoplasm Metastasis 122 Carcinoma, Hepatocellular 115 Multiple Myeloma 114 Lymphoma 114 Ovarian Neoplasms 95 Melanoma 95 Head and Neck Neoplasms 94 Brain Neoplasms 89 Leukemia 86 Recurrence 83 Leukemia, Lymphocytic, Chronic, B-Cell 83 Glioblastoma 76 Precursor Cell Lymphoblastic Leukemia-Lymphoma 75 Lymphoma, Non-Hodgkin 74 Colonic Neoplasms 74 Squamous Cell Carcinoma of Head and Neck 69 Lymphoma, Follicular 66 Lymphoma, Large B-Cell, Diffuse 64 Carcinoma, Renal Cell 62 Hematologic Neoplasms 61 Rectal Neoplasms 55 Stomach Neoplasms 52

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡